Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2851568 | American Heart Journal | 2009 | 7 Pages |
Abstract
There is clinical equipoise on the issue of optimal duration of dual antiplatelet treatment after percutaneous intervention with DES. The ISAR-SAFE trial aims to assess whether discontinuation of clopidogrel 6 months after DES implantation is noninferior to routine prolongation of such therapy out to 1 year.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Robert A. MB, MRCPI, Stefanie MD, Julinda MD, Raisuke MD, Steffen MD, Franz-Josef MD, JurriÑn M. MD, Albert MD, Adnan MD,